Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles

Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles

Dazhong Chen,1–3,* Xiaoli Pan,4,* Fangyuan Xie,5,* Ying Lu,2 Hao Zou,2 Chuan Yin,6 Yu Zhang,7 Jie Gao1,2 1Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China; 2Department of Pharmaceutical Sciences, Second Mi...

Full description

Bibliographic Details
Main Authors: Chen D, Pan X, Xie F, Lu Y, Zou H, Yin C, Zhang Y, Gao J
Format: Article
Language:English
Published: Dove Medical Press 2018-10-01
Series:International Journal of Nanomedicine
Subjects:
combined therapy
cancer stem cells
liver cancer
doxorubicin
elacridar
nanoparticles
Online Access:https://www.dovepress.com/codelivery-of-doxorubicin-and-elacridar-to-target-both-liver-cancer-ce-peer-reviewed-article-IJN

Internet

https://www.dovepress.com/codelivery-of-doxorubicin-and-elacridar-to-target-both-liver-cancer-ce-peer-reviewed-article-IJN

Similar Items